AusBiotech comments on government’s Entrepreneurs’ Infrastructure Program

26 June 2014
2019_biotech_test_vial_discovery_big

Trade body AusBiotech has made preliminary comment regarding the establishment of the Entrepreneurs’ Infrastructure Program (EIP), based on questions posed in the EIP Discussion Paper.

The Australian government announced in the May Federal Budget that it would close a number of programs (worth A$845.6 million), including Commercialization Australia (CA) and the Innovation Investment Fund (IIF), and establish the new Entrepreneurs’ Infrastructure Program (EIP), worth A$484.2 million over five years, “to implement its new approach to industry policy.” The government has advised that the EIP will be delivered through the new Single Business Service initiative via the Department of Industry, which will be accessible through one portal with one call center and helpline number. The portal, helpline and the initial services in the business management stream of the EIP are due to begin on July 1.

The government has advised that the services under the EIP will be refined following the stakeholder consultation and the EIP will support the government’s National Industry Investment and Competitiveness Agenda, which will be finalized in the coming months. The design of the EIP is also to complement other Government programs that provide support to business including the R&D Tax Incentive, Industry Skills Fund, Industry Growth Funds and the Manufacturing Transition Fund.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology